Form 4: Emergent BioSolutions Director Receives Stock Grant and Options

Emergent BioSolutions Inc. reports that Director Zsolt Harsanyi was granted restricted stock units and stock options on April 30, 2026, as part of his compensation for board service.

Summary

• Zsolt Harsanyi, a Director and Officer of Emergent BioSolutions Inc., received a grant of 25,344 restricted stock units (RSUs) and 11,296 stock options on April 30, 2026.
• The RSUs and stock options are part of his compensation for board and committee service.
• The RSUs represent a right to receive one share of common stock upon vesting, which occurs on the day prior to the one-year anniversary of the grant date, provided he remains on the board.
• The stock options have an exercise price of $7.99 and also vest on the same annual grant vesting date, contingent on continued board membership.
• Following these transactions, Harsanyi beneficially owns 149,076 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details routine compensation grants to a director rather than significant financial or strategic developments.

Positives

• Director Harsanyi received a significant grant of RSUs (25,344) and stock options (11,296), indicating continued investment in the company's future performance by a key executive.
• The grant is tied to continued board service, aligning management's interests with long-term shareholder value.
• The exercise price for the stock options is $7.99, which may represent an attractive entry point if the stock price appreciates.

Negatives

• The filing does not contain any negative financial results or operational setbacks.

Risks

• The vesting of RSUs and stock options is contingent upon Zsolt Harsanyi remaining a member of the Company's board of directors through the Annual Grant Vesting Date, implying a risk of forfeiture if he departs.
• The value of the RSUs and stock options is subject to the future performance and stock price of Emergent BioSolutions Inc.

Future Outlook

The future outlook for the granted RSUs and stock options is dependent on Zsolt Harsanyi remaining on the board and the future performance of Emergent BioSolutions Inc.'s stock price. The options expire on April 30, 2033.

Management Comments

• The RSUs represent a right to receive one share of Emergent BioSolutions Inc. common stock upon vesting.
• The stock options represent a right to purchase one share of the Company's common stock upon vesting at the exercise price.
• The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.

Industry Context

StockSavvy.ai notes that grants of stock options and RSUs to directors and officers are standard practice in the biopharmaceutical industry as a means to attract and retain talent, and to align executive compensation with shareholder interests and long-term company performance.

Stakeholder Impact

• Shareholders: The grants align director compensation with stock performance, potentially benefiting shareholders if the stock price increases. Dilution is minimal given the number of shares outstanding.
• Employees: The compensation structure for directors may influence overall compensation strategies within the company.
• Management: Reinforces the alignment of interests between directors and management with shareholders.

Next Steps

• Zsolt Harsanyi must remain a member of the board of directors through the Annual Grant Vesting Date for the RSUs and stock options to vest.
• The RSUs will vest on the day prior to the one-year anniversary of the grant date (April 30, 2027).
• The stock options will vest on the day prior to the one-year anniversary of the grant date (April 30, 2027) and expire on April 30, 2033.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Stock Options, Restricted Stock Units, RSUs, Director Compensation, Insider Trading, Beneficial Ownership, Securities Exchange Act